PDCD1LG2 and endometrial cancer: Subsequent clinical trials evaluating the efficacy of PD-L1, PD-L2, and PD-1 inhibitors demonstrated success in the treatment of solid tumors such as advanced melanoma, non-small cell lung cancer, renal cell carcinoma, colorectal cancer, and endometrial cancer [40].